Create a Profile
Idiopathic Pulmonary Fibrosis Study
If you or a loved one are living with Idiopathic Pulmonary Fibrosis (IPF) and not yet started treatment, consider participating in a new study at Accel Research Sites.
By participating, you can help doctors learn more about a new investigational medication for IPF.
If you or a loved one meet the following conditions, please contact us today to learn more:
- Age 40 years or above
- Diagnosed with IPF
- Have never been treated for IPF or have been treated with nintedanib (Ofev® or Vargatef®) for less than 6 full months
- Have never taken pirfenidone (Esbriet®, Pirespa®, or Etuary®)
Those who qualify for the study will receive:
- Study-related care at no cost
- Compensation for study-related participation
Create a Profile